Low-Count Quantitative SPECT for Men Treated With Radium-223
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak prostaty oporny na leczenie hormonalne z przerzutami do kości, powodujący objawy
- •Co najmniej 3 widoczne ogniska w kościach
- •Kwalifikacja do leczenia lekiem Xofigo
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Zdolność do zrozumienia badania i podpisania zgody
✗ Disqualifies
- •Przerzuty rozsiane głównie poza kościami (w narządach wewnętrznych)
- •Inne nowotwory, które mogą wpłynąć na wyniki badania
- •Niekontrolowane infekcje lub poważne problemy z sercem
- •Stosowanie innych leków radioaktywnych jednocześnie
- •Niemożność pozostania nieruchomym przez 45-60 minut podczas badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Washington University School of Medicine
St Louis, United States
Trial contact
Abhinav K Jha, Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.